| | FDA updates prescribing information for topical calcineurin inhibitors - Novartis.com (Site not responding. Last check: 2007-10-03) |
 | | Elidel remains indicated for short-term and non-continuous chronic treatment of mild to moderate eczema in patients over two years of age, who have failed to respond adequately to other therapies, or where other therapies are inadvisable. |
 | | Support for the efficacy and safety of Elidel and topical calcineurin inhibitors in general has been expressed by many professional associations and societies worldwide representing a total of 90,000 dermatologists and other specialists, and by a number of leading groups representing patients and their families. |
 | | FDA’s review of the safety of topical calcineurin inhibitors was based on a theoretical risk stemming from the adverse events associated with the systemic use of calcineurin inhibitors in animal studies and transplant patients. |
| www.novartis.com /news/en/20060120_elidel_fda_update.shtml (975 words) |